H.R. 5115 · 109th Congress
U.S. Healthcare Technologies Competitiveness Act of 2006
Key: what the circles and colors mean
Each circle is a bill. The ring fills as it moves through Congress:
Under the number: the Yea · Nay count of its final (or latest) recorded vote. On a member's page, the small badge is how that member voted: Y Yea / Aye, N Nay / No, P Present, – Not voting.
Gold and violet are only for Yea and Nay; they never mean a party. A member's party is the letter on their photo.
Never voted on. It didn't reach a floor vote before the 109th Congress ended, so it expired. A bill has to be introduced again to be considered in a new Congress.
R
HartSponsor3 cosponsors · 3 R
2 signed on when it was introduced; the rest joined later. Cosponsors who withdrew aren't shown.
U.S. Healthcare Technologies Competitiveness Act of 2006 - Amends the Internal Revenue Code to provide tax incentives for investment in biomedical research corporations and related entities, by: (1) exempting investors in biomedical research corporations from limitations on net operating losses acquired through stock sales and mergers involving such…
What it does: CRS summary · Introduced in House · Apr 6, 2006
U.S. Healthcare Technologies Competitiveness Act of 2006 - Amends the Internal Revenue Code to provide tax incentives for investment in biomedical research corporations and related entities, by: (1) exempting investors in biomedical research corporations from limitations on net operating losses acquired through stock sales and mergers involving such corporations; (2) permitting a complete offset against the alternative minimum tax for the net operating losses of biomedical research corporations; (3) making permanent and increasing the rates for the tax credit for increasing research activities; (4) allowing tax credits for countermeasures equity investments and research expenses, qualified medical innovation expenses, equity investments in incubational companies, and investment in qualified biotechnology zone bonds; (5) accelerating eligibility for the tax credit for orphan drug expenses; (6) allowing expensing of biotechnology science park property and medical research equipment; (7) allowing deferral of the tax on gain from the sale of stock in a biomedical research corporation; (8) increasing the tax deductibility of capital losses on the sale of stock in biomedical research corporations; and (9) modifying passive loss deduction rules and S corporation shareholder requirements for biomedical research corporations.
Written by the nonpartisan Congressional Research Service. All summary versions on Congress.gov
About this bill and sources
Official title: U.S. Healthcare Technologies Competitiveness Act of 2006
Latest action (Apr 6, 2006): Referred to the House Committee on Ways and Means.
Policy area: Taxation · Origin: House · Introduced: Apr 6, 2006
Official page on Congress.gov · Bill text (GovInfo) · Status record (XML)
No recorded floor vote found.